FDA orphan drug designations for lysosomal storage disorders: a cross sectional analysis
Purpose To provide a quantitative clinical-regulatory insight into the status of FDA orphan drug designations for compounds intended to treat lysosomal storage disorders (LSD’s). - Methods Assessment of the drug pipeline through analysis of the FDA database for orphan drug designations with descript...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) Kapitel/Artikel |
| Sprache: | Englisch |
| Veröffentlicht: |
January 14, 2020
|
| In: |
medRxiv
Year: 2020, Pages: 1-29 |
| DOI: | 10.1101/2020.01.05.20016568 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1101/2020.01.05.20016568 Verlag, kostenfrei, Volltext: https://www.medrxiv.org/content/10.1101/2020.01.05.20016568v2 |
| Verfasserangaben: | Sven F. Garbade PhD, Matthias Zielonka MD, Konstantin Mechler MD, Stefan Kölker MD, Georg F. Hoffmann MD, Christian Staufner MD, Eugen Mengel MD and Markus Ries MD PhD |
Search Result 1